The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
The status of platinum anticancer drugs in the clinic and in clinical trials
Open accessAbstract
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations. During this time there have been more failures than successes with the development of 14 drugs being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial (satraplatin, picoplatin, Lipoplatin and ProLindac). No new small molecule platinum drug has entered clinical trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade. In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials, and discuss the results in the context of where we believe the field will develop over the next decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Welt, F. G. P., & Edelman, E. R. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)90003-x · Cited by 863
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Methods for Genotyping Single Nucleotide Polymorphisms
Kwok, P.-Y. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.235 · Cited by 580
Medical aspects of sulphur mustard poisoning
Kehe, K., & Szinicz, L. (2005) · Toxicology · doi:10.1016/j.tox.2005.06.014 · Cited by 439
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Metal complexes in cancer therapy – an update from drug design perspective
Ndagi, U., Mhlongo, N., & Soliman, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s119488 · Cited by 935
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Carbon nanotubes for delivery of small molecule drugs
Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., & Pastorin, G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.005 · Cited by 585
Redox activation of metal-based prodrugs as a strategy for drug delivery
Graf, N., & Lippard, S. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.007 · Cited by 523
Metal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515
Jeyaraj, M., Gurunathan, S., Qasim, M., Kang, M.-H., & Kim, J.-H. (2019) · Nanomaterials · doi:10.3390/nano9121719 · Cited by 481
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., & Yu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00343 · Cited by 479
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., Yoo, H., Lin, W., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 440
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Bioactive Luminescent Transition‐Metal Complexes for Biomedical Applications
Ma, D., He, H., Leung, K., Chan, D. S., & Leung, C. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208414 · Cited by 388
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Ye, M., Han, Y., Tang, J., Piao, Y., Liu, X., Zhou, Z., Gao, J., Rao, J., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201702342 · Cited by 338
Park, G. Y., Wilson, J. J., Song, Y., & Lippard, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207670109 · Cited by 330
Min, Y., Li, J., Liu, F., Yeow, E. K. L., & Xing, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308834 · Cited by 309
Bioactive iridium and rhodium complexes as therapeutic agents
Leung, C.-H., Zhong, H.-J., Chan, D. S.-H., & Ma, D.-L. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.01.034 · Cited by 303
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Carbon nanotubes as cancer therapeutic carriers and mediators
Son, K. H., Hong, J. H., & Lee, J. W. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s112660 · Cited by 292
Platinum(iv) anticancer prodrugs – hypotheses and facts
Gibson, D. (2016) · Dalton Transactions · doi:10.1039/c6dt01414c · Cited by 286
The elements of life and medicines
Chellan, P., & Sadler, P. J. (2015) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2014.0182 · Cited by 274
Wang, P., Gong, Q., Hu, J., Li, X., & Zhang, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01704 · Cited by 270
Functionalization of Platinum Complexes for Biomedical Applications
Wang, X., Wang, X., & Guo, Z. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00203 · Cited by 268
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Self-citationNanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Parker, J. P., Nimir, H., Griffith, D. M., Duff, B., Chubb, A. J., Brennan, M. P., Morgan, M. P., Egan, D. A., & Marmion, C. J. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.03.011 · Cited by 32
Biswas, R., Chung, P.-S., Moon, J. H., Lee, S.-H., & Ahn, J.-C. (2014) · Lasers in Medical Science · doi:10.1007/s10103-013-1452-9 · Cited by 19
Metadata
- Authors
- Wheate, N. J., Walker, S., Craig, G. E., & Oun, R.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2010
- Volume
- 39
- Issue
- 35
- Pages
- 8113
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2101539565
- Cited by
- 1,634
- References
- 71
- FWCI
- 30.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.